Education
About Us
Working with TipRanks
Follow Us
Vincerx Pharma Inc (VINC)
:VINC
VINC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.48 - $136.80
Previous CloseN/A
Volume2.27M
Average Volume (3M)1.17M
Market Cap
$3.01M
Enterprise Value$6.71M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.49
Next Earnings
May 08, 2025EPS Estimate
-3.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.56
Shares Outstanding5,234,277
10 Day Avg. Volume382,896
30 Day Avg. Volume1,174,433
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.42
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market Cap2.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.25
Forecast
1Y Price Target
$2.00Price Target Upside244.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Vincerx Pharma Inc News
---
Bulls Say, Bears Say
Bulls Say
Analyst's RecommendationAnalyst continues to have a positive view on VINC at current levels despite the challenges.
Program DataVINC provided an early but encouraging data update from the VIP943 program, highlighted by early signs of activity with VIP943.
Safety And TolerabilityVIP943 has shown favorable safety and tolerability, with no dose-limiting toxicities reported in the 22 patients treated.
Bears Say
Efficacy ResultsFor VIP236, in 20 efficacy-evaluable patients, 9 patients had stable disease, but there were no patients who achieved objective response.
Financial PerformanceVINC ended with $10.1M in cash and equivalents, indicating limited financial resources.
Strategic DependencyThe company continues to look for a partner to advance development of enitociclib and VIP236, suggesting dependency on external collaboration for progress.
---
Ownership Overview
10.77%
Insiders
2.27% Mutual Funds
0.03% Other Institutional Investors
85.23% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VINC FAQ
What was Vincerx Pharma Inc’s price range in the past 12 months?
Vincerx Pharma Inc lowest stock price was $0.48 and its highest was $136.80 in the past 12 months.
What is Vincerx Pharma Inc’s market cap?
Vincerx Pharma Inc’s market cap is $3.01M.
When is Vincerx Pharma Inc’s upcoming earnings report date?
Vincerx Pharma Inc’s upcoming earnings report date is May 08, 2025 which is in 35 days.
How were Vincerx Pharma Inc’s earnings last quarter?
Vincerx Pharma Inc released its earnings results on Apr 01, 2025. The company reported -$3.569 earnings per share for the quarter, missing the consensus estimate of -$3.4 by -$0.169.
Is Vincerx Pharma Inc overvalued?
According to Wall Street analysts Vincerx Pharma Inc’s price is currently Undervalued.
Does Vincerx Pharma Inc pay dividends?
Vincerx Pharma Inc does not currently pay dividends.
What is Vincerx Pharma Inc’s EPS estimate?
Vincerx Pharma Inc’s EPS estimate is -3.4.
How many shares outstanding does Vincerx Pharma Inc have?
Vincerx Pharma Inc has 5,234,277 shares outstanding.
What happened to Vincerx Pharma Inc’s price movement after its last earnings report?
Vincerx Pharma Inc reported an EPS of -$3.569 in its last earnings report, missing expectations of -$3.4. Following the earnings report the stock price went up 9.434%.
Which hedge fund is a major shareholder of Vincerx Pharma Inc?
Among the largest hedge funds holding Vincerx Pharma Inc’s share is Woodline Partners LP. It holds Vincerx Pharma Inc’s shares valued at 0.
---
Company Description
Vincerx Pharma Inc
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
---
VINC Stock 12 Month Forecast
Average Price Target
$2.00
▲(244.83% Upside)
Technical Analysis
Best Analysts Covering VINC
1 Year
1 Year Success Rate
1/19 ratings generated profit
1 Year Average Return
-40.71%
reiterated a buy rating 5 months ago
Copying Jonathan Chang's trades and holding each position for 1 Year would result in 5.26% of your transactions generating a profit, with an average return of -40.71% per trade.
---